DK1530628T3 - Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser - Google Patents
Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelserInfo
- Publication number
- DK1530628T3 DK1530628T3 DK03792365.3T DK03792365T DK1530628T3 DK 1530628 T3 DK1530628 T3 DK 1530628T3 DK 03792365 T DK03792365 T DK 03792365T DK 1530628 T3 DK1530628 T3 DK 1530628T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell lysates
- tumor cell
- induced tumor
- lysate
- immunogenic compounds
- Prior art date
Links
- 239000013592 cell lysate Substances 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 210000004881 tumor cell Anatomy 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 4
- 239000006166 lysate Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002934 lysing effect Effects 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02018512 | 2002-08-16 | ||
| PCT/EP2003/009140 WO2004018659A1 (en) | 2002-08-16 | 2003-08-18 | Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1530628T3 true DK1530628T3 (da) | 2011-01-10 |
Family
ID=31896837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03792365.3T DK1530628T3 (da) | 2002-08-16 | 2003-08-18 | Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7595192B2 (da) |
| EP (1) | EP1530628B1 (da) |
| AT (1) | ATE482720T1 (da) |
| AU (1) | AU2003260426A1 (da) |
| DE (1) | DE60334382D1 (da) |
| DK (1) | DK1530628T3 (da) |
| ES (1) | ES2353753T3 (da) |
| SI (1) | SI1530628T1 (da) |
| WO (1) | WO2004018659A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003260426A1 (en) | 2002-08-16 | 2004-03-11 | Glycotope Gmbh | Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
| EP1654353B1 (en) | 2003-08-18 | 2013-05-22 | Glycotope GmbH | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof |
| CA2557725C (en) * | 2004-02-13 | 2015-06-30 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
| US20060140983A1 (en) * | 2004-10-25 | 2006-06-29 | Baylor Research Institute | Dendritic cells loaded with heat shocked melanoma cell bodies |
| WO2007001200A1 (fr) * | 2005-06-23 | 2007-01-04 | Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' | Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules |
| GB0601598D0 (en) * | 2006-01-26 | 2006-03-08 | Stathopoulos Apostolos | Method |
| EP2428224B1 (en) | 2006-09-10 | 2016-12-21 | Glycotope GmbH | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| CL2007002825A1 (es) | 2007-09-28 | 2008-05-30 | Univ De Chile Oncobiomed | Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| BR112014004065A2 (pt) | 2011-08-22 | 2017-03-14 | Glycotope Gmbh | micro-organismos carregando um antígeno de tumor |
| CN103800896A (zh) * | 2012-11-15 | 2014-05-21 | 厦门鹭佳生物科技有限公司 | 一种自体肿瘤疫苗的制备方法及其应用 |
| KR102367009B1 (ko) * | 2012-12-28 | 2022-02-24 | 암페라 비.브이. | 면역원성 용해물의 제조방법, 이로부터 얻어진 면역원성 용해물, 상기 용해물이 로딩된 수지상 세포 및 상기 용해물 또는 상기 수지상 세포를 포함하는 약학 조성물 |
| DK3794042T3 (da) | 2018-05-18 | 2024-04-15 | Daiichi Sankyo Co Ltd | Anti-muc1-exatecet-antistof-lægemiddelkonjugat |
| EP4003424A4 (en) * | 2019-07-22 | 2023-11-22 | Todd Alamin | CELL TREATMENTS AND REPERFUSION THERAPEUTIC METHODS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4931275A (en) | 1985-12-02 | 1990-06-05 | Yeda Research & Development Co., Ltd. | Anti-tumor vaccines and their preparation |
| WO1994029469A2 (en) | 1993-06-07 | 1994-12-22 | Vical Incorporated | Plasmids suitable for gene therapy |
| US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
| US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| AU723325B2 (en) | 1995-06-23 | 2000-08-24 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
| EP0906444A1 (de) | 1996-04-19 | 1999-04-07 | Gabriele Pecher | Gentransfizierte humane dendritische zellen, ihre herstellung und ihre verwendung, bevorzugt als vakzine |
| US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US6984384B1 (en) * | 1999-09-30 | 2006-01-10 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
| SI1529060T1 (sl) | 2002-07-22 | 2015-01-30 | Glycotope Gmbh | Postopek za proizvodnjo imunostimulacijskih mucinov (MUCI) |
| AU2003260426A1 (en) | 2002-08-16 | 2004-03-11 | Glycotope Gmbh | Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
| EP1654353B1 (en) | 2003-08-18 | 2013-05-22 | Glycotope GmbH | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof |
-
2003
- 2003-08-18 AU AU2003260426A patent/AU2003260426A1/en not_active Abandoned
- 2003-08-18 DE DE60334382T patent/DE60334382D1/de not_active Expired - Lifetime
- 2003-08-18 EP EP03792365A patent/EP1530628B1/en not_active Expired - Lifetime
- 2003-08-18 ES ES03792365T patent/ES2353753T3/es not_active Expired - Lifetime
- 2003-08-18 DK DK03792365.3T patent/DK1530628T3/da active
- 2003-08-18 WO PCT/EP2003/009140 patent/WO2004018659A1/en not_active Application Discontinuation
- 2003-08-18 US US10/524,738 patent/US7595192B2/en not_active Expired - Fee Related
- 2003-08-18 AT AT03792365T patent/ATE482720T1/de active
- 2003-08-18 SI SI200331930T patent/SI1530628T1/sl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7595192B2 (en) | 2009-09-29 |
| DE60334382D1 (de) | 2010-11-11 |
| ES2353753T3 (es) | 2011-03-04 |
| ATE482720T1 (de) | 2010-10-15 |
| AU2003260426A1 (en) | 2004-03-11 |
| WO2004018659A1 (en) | 2004-03-04 |
| SI1530628T1 (sl) | 2011-02-28 |
| US20060127419A1 (en) | 2006-06-15 |
| EP1530628B1 (en) | 2010-09-29 |
| EP1530628A1 (en) | 2005-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1530628T3 (da) | Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser | |
| WO2021155243A8 (en) | Respiratory virus immunizing compositions | |
| WO2019126634A3 (en) | Targeted integration of nucleic acids | |
| WO2014028453A3 (en) | Natural killer cells and uses thereof | |
| BR112013000822A2 (pt) | método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais | |
| WO2017191274A3 (en) | Rna encoding a therapeutic protein | |
| BR112015015031A2 (pt) | processo de glicoconjugação | |
| MX2018004600A (es) | Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. | |
| WO2021064137A3 (en) | Multi-specific binding proteins for cancer treatment | |
| BR112015023036A2 (pt) | método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina | |
| TW200716671A (en) | Improved nanobodies against tumor necrosis factor-alpha | |
| BR112022008750A2 (pt) | Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico | |
| BR112013031084A2 (pt) | meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas | |
| PH12021551241A1 (en) | Expansion of natural killer cells and ilc3 cells with novel aromatic compounds | |
| BRPI0510719A (pt) | derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos | |
| MY187358A (en) | Modified release orally administered amino acid formulations | |
| EP1712243A4 (en) | GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE | |
| WO2008056174A3 (en) | Novel compositions and uses thereof | |
| CL2020002566A1 (es) | Composiciones aav, métodos de fabricación y métodos de uso | |
| MX2021011608A (es) | Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines. | |
| BRPI0514884A (pt) | composição vacinal para gerar resposta imune celular e humoral protetora contra a infecção pelo vìrus de hepatite c | |
| WO2006002627A3 (en) | Chicken deoxycytidine and deoxyadenosine kinase enzymes and their use | |
| WO2009062260A8 (en) | Therapy for multiple sclerosis | |
| DK1509244T3 (da) | Ny fremgangsmåde og præparat til at producere en cellulær allogen vaccine | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 |